Biomerica Appoints Eric B. Chin to Board of Directors and Audit Committee Chair

Core Viewpoint - Biomerica, Inc. has appointed Eric B. Chin to its Board of Directors, enhancing its corporate governance and financial oversight as it scales commercialization efforts for its diagnostic and therapeutic products [1][7]. Group 1: Appointment Details - Eric B. Chin has been appointed as Chairperson of the Audit Committee and a member of the Nominating and Corporate Governance Committee and the Compensation Committee, effective June 4, 2025 [1]. - Chin replaces Cathy Coste, whose resignation was not due to any disagreement with the company [3]. Group 2: Eric B. Chin's Background - Chin is an accomplished financial executive with over 20 years of experience in public and private healthcare organizations [2][7]. - He currently serves as CFO of Akido Labs, where he successfully raised $60 million in recent financing [2][7]. - His previous roles include executive positions at Astrana Health, Public Storage, and Alexandria Real Estate Equities, and he began his career at Ernst & Young LLP [2]. Group 3: Company Overview - Biomerica, Inc. develops, patents, manufactures, and markets advanced diagnostic and therapeutic products aimed at enhancing health and reducing healthcare costs, primarily focusing on gastrointestinal and inflammatory diseases [4]. - The company's inFoods IBS test assesses patients' immunoreactivity to specific foods, providing targeted dietary recommendations to alleviate IBS symptoms [5].